Remission, a Therapeutic Goal in Inflammatory Arthropathies?: Clinical Data from Adalimumab Studies

ISSN： 0012-6667

Source： Drugs, Vol.66, Iss.14, 2006-01, pp. : 1783-1795

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adalimumab: Vitiligo?: case report

Reactions Weekly, Vol. 1, Iss. 1359, 2011-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Studies of Long-Term Use of Antidepressants: How Should the Data from Them be Interpreted?

By El-Mallakh Rif S. Briscoe Brian

CNS Drugs, Vol. 26, Iss. 2, 2012-02 ,pp. : 97-109

Adis International

Access to resources Recommend Favorite

Adalimumab: Optic neuritis and multiple sclerosis?: case report

Reactions Weekly, Vol. 1, Iss. 1334, 2011-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Adalimumab/etanercept: Sarcoidosis?: 2 case reports

Reactions Weekly, Vol. 1, Iss. 1290, 2010-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Adalimumab/etanercept: Tubercular meningitis in a child?: case report

Reactions Weekly, Vol. 1, Iss. 1352, 2011-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite